[go: up one dir, main page]

PE20110707A1 - Variantes de inmunoglobulinas - Google Patents

Variantes de inmunoglobulinas

Info

Publication number
PE20110707A1
PE20110707A1 PE2011000886A PE2011000886A PE20110707A1 PE 20110707 A1 PE20110707 A1 PE 20110707A1 PE 2011000886 A PE2011000886 A PE 2011000886A PE 2011000886 A PE2011000886 A PE 2011000886A PE 20110707 A1 PE20110707 A1 PE 20110707A1
Authority
PE
Peru
Prior art keywords
whose substitution
substitution
whose
variant
antibody
Prior art date
Application number
PE2011000886A
Other languages
English (en)
Inventor
Lisa A Damico
Napoleone Ferrara
Henry B Lowman
Yu-Ju G Meng
Yik Andy Yeung
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110707(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20110707A1 publication Critical patent/PE20110707A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANIZADO QUE ES UNA INMUNOGLOBULINA IgG VARIANTE QUE COMPRENDE UNA REGION Fc QUE TIENE DOS O MAS SUSTITUCIONES DE AMINOACIDOS EN LOS RESIDUOS AMINOACIDOS A) 251 CUYA SUSTITUCION ES POR ACIDO ASPARTICO O ACIDO GLUTAMICO; B) 252 CUYA SUSTITUCION ES POR TIROSINA; C) 307 CUYA SUSTITUCION ES POR GLUTAMINA; D) 308 CUYA SUSTITUCION ES POR PROLINA; E) 378 CUYA SUSTITUCION ES POR VALINA; F) 428 CUYA SUSTITUCION ES POR LEUCINA; G) 430 CUYA SUSTITUCION ES POR ALANINA O LISINA; H) 434 CUYA SUSTITUCION ES POR ALANINA, SERINA O TIROSINA; Y I) 436 CUYA SUSTITUCION ES POR ISOLEUCINA; DONDE LA IgG VARIANTE ES UN ANTICUERPO ANTI-VEGF VARIANTE DE BEVACIZUMAB. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, CANCER DE OVARIO, GLIOBLASTOMA, CANCER DE MAMA
PE2011000886A 2008-10-14 2009-10-13 Variantes de inmunoglobulinas PE20110707A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10508608P 2008-10-14 2008-10-14
US15213109P 2009-02-12 2009-02-12
US17176809P 2009-04-22 2009-04-22
US22051409P 2009-06-25 2009-06-25

Publications (1)

Publication Number Publication Date
PE20110707A1 true PE20110707A1 (es) 2011-10-11

Family

ID=41571534

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011000886A PE20110707A1 (es) 2008-10-14 2009-10-13 Variantes de inmunoglobulinas
PE2015000431A PE20150682A1 (es) 2008-10-14 2009-10-13 Variantes de inmunoglobulinas y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2015000431A PE20150682A1 (es) 2008-10-14 2009-10-13 Variantes de inmunoglobulinas y sus usos

Country Status (21)

Country Link
US (3) US20100098730A1 (es)
EP (2) EP3524620A1 (es)
JP (2) JP5913980B2 (es)
KR (3) KR102100066B1 (es)
CN (3) CN104447990B (es)
AR (1) AR073829A1 (es)
AU (1) AU2009303526B2 (es)
BR (1) BRPI0914091B1 (es)
CA (1) CA2739429C (es)
CL (1) CL2015000148A1 (es)
ES (1) ES2828721T3 (es)
IL (2) IL212048B (es)
MX (1) MX2011004001A (es)
PE (2) PE20110707A1 (es)
PH (1) PH12016500081B1 (es)
PL (1) PL2352521T3 (es)
RU (1) RU2536937C2 (es)
SG (2) SG10201605250SA (es)
TW (2) TWI572357B (es)
WO (1) WO2010045193A1 (es)
ZA (1) ZA201102413B (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
ATE430580T1 (de) * 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
IN2014DN10515A (es) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
US20080127996A1 (en) * 2006-12-04 2008-06-05 Weinhold Dennis G Method and apparatus to remediate an acid and/or liquid spill
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
KR101922788B1 (ko) 2007-09-26 2018-11-27 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
NZ600826A (en) 2009-12-23 2014-09-26 Genentech Inc Anti-bv8 antibodies and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
BR112012027001A2 (pt) 2010-04-23 2016-07-19 Genentech Inc produção de proteínas heteromultiméricas
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
MX340498B (es) 2011-06-30 2016-07-11 Chugai Pharmaceutical Co Ltd Polipeptido heterodimerizado.
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
KR20200120743A (ko) * 2011-07-06 2020-10-21 젠맵 비. 브이 항체 변이체 및 그의 용도
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CA2850194C (en) 2011-09-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens
RU2722829C9 (ru) 2011-09-30 2020-09-22 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, индуцирующая иммунный ответ на антиген-мишень
US20150299313A1 (en) 2011-10-05 2015-10-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
KR102132997B1 (ko) * 2011-10-11 2020-07-14 메디뮨 엘엘씨 Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CN104204204A (zh) 2012-02-09 2014-12-10 中外制药株式会社 抗体的Fc区变异体
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Ｆｃ-수용체 기재 친화성 크로마토그래피
TWI877445B (zh) 2012-02-24 2025-03-21 日商中外製藥股份有限公司 經FcγRIIB促進抗原消失之抗原結合分子
ES2856272T3 (es) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
CN104487457B (zh) 2012-05-30 2018-01-26 中外制药株式会社 靶组织特异性抗原结合分子
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
EP3632462A1 (en) * 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
BR112015000167B1 (pt) * 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE FC RII SPECIFIC FC ANTIBODY
DK2889377T3 (da) 2012-08-24 2020-03-30 Chugai Pharmaceutical Co Ltd Fc?RIIb-Specifik Fc-regionsvariant
JP6433297B2 (ja) 2012-12-27 2018-12-05 中外製薬株式会社 ヘテロ二量化ポリペプチド
KR20160007478A (ko) * 2013-01-10 2016-01-20 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
US11220556B2 (en) * 2013-03-15 2022-01-11 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
RU2019108429A (ru) * 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
KR20160104636A (ko) 2014-01-15 2016-09-05 에프. 호프만-라 로슈 아게 단백질 Ａ-결합이 개선된 Ｆｃ-영역 변이체
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3116486B1 (en) 2014-03-14 2019-12-04 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
CA2938722A1 (en) 2014-03-21 2015-09-24 F. Hoffmann-La Roche Ag In vitro prediction of in vivo half-life of antibodies
EP3140392B1 (en) 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107108720A (zh) * 2014-11-06 2017-08-29 豪夫迈·罗氏有限公司 具有改变的FCRN结合的Fc区变体及其使用方法
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
KR20230027321A (ko) 2015-12-18 2023-02-27 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
CN116239693A (zh) * 2016-03-14 2023-06-09 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
RU2735680C2 (ru) 2016-03-14 2020-11-05 Биотест Аг Лечение тяжелой внебольничной пневмонии
EP3463461A4 (en) 2016-05-27 2020-05-20 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
KR102680483B1 (ko) 2016-06-17 2024-07-01 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
MX2019001458A (es) * 2016-08-02 2019-07-04 Visterra Inc Polipeptidos modificados y usos de los mismos.
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
ES2902670T3 (es) * 2017-01-13 2022-03-29 Taizhou Hanzhong Biopharmaceutics Inc Anticuerpo monoclonal contra PD-1 y aplicaciones del mismo
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
CN107748259A (zh) * 2017-07-26 2018-03-02 东曜药业有限公司 一种FcRn受体的ELISA检测方法
EP3658184B1 (en) 2017-07-27 2023-09-06 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
US12128101B2 (en) 2017-10-26 2024-10-29 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
JP7039694B2 (ja) 2017-10-31 2022-03-22 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
WO2019098212A1 (en) 2017-11-14 2019-05-23 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
FR3076294B1 (fr) 2017-12-29 2022-01-28 Lab Francais Du Fractionnement Procede de purification d'anticorps a partir de lait brut
CN108101992B (zh) * 2017-12-31 2021-03-26 武汉班科生物技术股份有限公司 与新生的Fc受体结合增强的CH2结构域突变体及其制备方法与应用
JP2018138022A (ja) * 2018-02-23 2018-09-06 ゲンマブ ビー．ブイ． ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
CN108519383B (zh) * 2018-04-08 2020-08-14 上海理工大学 一种全波段生物显色实验的检测方法
WO2019231983A1 (en) 2018-05-31 2019-12-05 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
WO2019235426A1 (ja) * 2018-06-04 2019-12-12 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
CA3102829A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
IL280720B2 (en) 2018-08-10 2025-04-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
AU2019370295A1 (en) 2018-10-30 2021-06-03 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
BR112021014574A2 (pt) 2019-01-23 2021-10-05 Encefa Competidores cd31 e usos dos mesmos
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
AU2020351234A1 (en) * 2019-09-18 2022-04-28 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CD38
EP4031579A2 (en) 2019-09-18 2022-07-27 F. Hoffmann-La Roche AG Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022007479A (es) 2019-12-18 2022-06-29 Hoffmann La Roche Anticuerpos anti-ccl2 biespecificos.
CN113637084B (zh) * 2020-05-11 2025-08-01 上海康景生物医药科技有限公司 生物大分子靶向特异性补体抑制剂及其制备方法与应用
EP4355775A1 (en) 2021-06-18 2024-04-24 F. Hoffmann-La Roche AG Bispecific anti-ccl2 antibodies
AU2023334360A1 (en) * 2022-09-02 2025-03-06 Zoetis Services Llc Equine antibody mutants
CN121319170A (zh) * 2024-07-12 2026-01-13 菲鹏生物股份有限公司 免疫球蛋白及其用途

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
US5278299A (en) * 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3144193A (en) * 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP4046354B2 (ja) * 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
ATE501170T1 (de) 1997-04-07 2011-03-15 Genentech Inc Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6602684B1 (en) * 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
SI1308455T1 (sl) 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
ES2694002T3 (es) * 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP2270150B2 (en) * 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
RU2317999C2 (ru) 2000-02-25 2008-02-27 Те Гавернмент Оф Те Юнайтед Стейтс, Эз Репризентед Бай Те Секретари Оф Те Департмент Оф Хелт Энд Хьюман Сервисез SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
IL151348A0 (en) * 2000-04-13 2003-04-10 Univ Rockefeller Enhancement of antibody-mediated immune responses
JP2003533987A (ja) 2000-05-19 2003-11-18 イス ケミカル カンパニー リミテッド 表皮成長因子収容体に対するヒト化抗体
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
DE60128685T2 (de) 2000-06-23 2009-03-05 Bayer Schering Pharma Aktiengesellschaft Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP3690043A1 (en) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
US6480405B2 (en) * 2000-11-17 2002-11-12 Texas Instruments Incorporated Full-wave rectifier
ES2727425T3 (es) * 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
IL156955A0 (en) * 2001-01-17 2004-02-08 Genecraft Inc Binding domain-immunoglobulin fusion proteins
ATE507839T1 (de) * 2001-04-02 2011-05-15 Genentech Inc Kombinationstherapie
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2002302848C8 (en) 2001-06-14 2010-02-04 Cambridge Enterprise Limited CD4-specific antibody TRX1 and uses therefor
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
ATE430580T1 (de) * 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1490677A4 (en) 2002-02-27 2006-01-18 California Inst Of Techn COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1500698B1 (en) 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
CA2500895A1 (en) 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7220833B2 (en) 2002-12-03 2007-05-22 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2368578A1 (en) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
BRPI0410745A (pt) 2003-05-22 2006-06-27 Abbott Lab inibidores de indazol, benzisoxazol e benzisotiazol quinase
WO2005000900A1 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
WO2005035727A2 (en) 2003-10-09 2005-04-21 Ambrx, Inc. Polymer derivatives
KR101364902B1 (ko) 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US7118999B2 (en) * 2004-01-16 2006-10-10 International Business Machines Corporation Method and apparatus to increase strain effect in a transistor channel
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
DK2213683T3 (da) * 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CN101098890B (zh) * 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2325206B1 (en) * 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
JP2008526205A (ja) * 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
CN101304791B (zh) * 2005-09-07 2010-06-16 帕尔坎Y宾公司 包括改进的三维拼板的玩具
MX2008011785A (es) * 2006-03-16 2008-09-25 Genentech Inc Metodos de tratamiento de lupus utilizando anticuerpos cd4.
US8652466B2 (en) * 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
ES2742268T3 (es) * 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn

Also Published As

Publication number Publication date
CN110317272A (zh) 2019-10-11
TW201542228A (zh) 2015-11-16
SG10201605250SA (en) 2016-08-30
TWI572357B (zh) 2017-03-01
CN104447990A (zh) 2015-03-25
US20210002359A1 (en) 2021-01-07
PH12016500081A1 (en) 2017-01-16
BRPI0914091A2 (pt) 2016-09-27
KR102100066B1 (ko) 2020-04-10
JP2016026144A (ja) 2016-02-12
ES2828721T3 (es) 2021-05-27
HK1209130A1 (en) 2016-03-24
EP2352521A1 (en) 2011-08-10
KR20110070914A (ko) 2011-06-24
MX2011004001A (es) 2011-05-19
US20100098730A1 (en) 2010-04-22
PE20150682A1 (es) 2015-05-20
CA2739429A1 (en) 2010-04-22
PH12016500081B1 (en) 2017-01-16
AR073829A1 (es) 2010-12-01
CA2739429C (en) 2020-12-22
AU2009303526A1 (en) 2010-04-22
WO2010045193A1 (en) 2010-04-22
KR20180027609A (ko) 2018-03-14
EP2352521B1 (en) 2020-09-16
CN104447990B (zh) 2019-07-19
KR101834999B1 (ko) 2018-03-06
JP2012505833A (ja) 2012-03-08
HK1163550A1 (zh) 2012-09-14
JP6122072B2 (ja) 2017-04-26
EP3524620A1 (en) 2019-08-14
KR20190025057A (ko) 2019-03-08
BRPI0914091B1 (pt) 2022-05-10
IL212048B (en) 2020-02-27
CN102245208A (zh) 2011-11-16
AU2009303526B2 (en) 2015-01-15
RU2536937C2 (ru) 2014-12-27
TW201023884A (en) 2010-07-01
CL2015000148A1 (es) 2015-04-24
JP5913980B2 (ja) 2016-05-11
TWI572359B (zh) 2017-03-01
PL2352521T3 (pl) 2021-03-08
ZA201102413B (en) 2012-06-27
IL264138A (en) 2019-02-28
CN102245208B (zh) 2016-03-16
SG195558A1 (en) 2013-12-30
RU2011119447A (ru) 2012-11-27
IL212048A0 (en) 2011-06-30
US20140294810A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
PE20110707A1 (es) Variantes de inmunoglobulinas
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
MY201701A (en) Optimized antibody compositions for treatment of ocular disorders
PE20200695A1 (es) Anticuerpos que reconocen tau
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20091352A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
EA201290173A1 (ru) Антитела против эндоглина
EA201691251A1 (ru) Цитотоксические пептиды и их конъюгаты
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
AR085198A1 (es) Composicion farmaceutica
PE20141045A1 (es) Proteinas de union a bcma (cd269/tnfrsf17)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
EA202091747A1 (ru) Составы антитела b7-h4
PE20160993A1 (es) Nuevos anticuerpos anti-dpep3 y metodos de uso
PE20140448A1 (es) Moleculas de union biespecificas que se unen a vegf y ang2
NO20074563L (no) Novel anti-plgf antibody
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
UA114604C2 (uk) Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9)
PE20081634A1 (es) Fab ab pegilado
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion

Legal Events

Date Code Title Description
FG Grant, registration